How much funding has Biosplice Therapeutics raised?

Biosplice Therapeutics has raised $120.0M in total funding, most recently a Series B round.

Who are Biosplice Therapeutics's investors?

Biosplice Therapeutics's investors include SymBiosis II, Sands Capital, Eventide Asset Management, aMoon, Verition Fund Management.

When was Biosplice Therapeutics founded?

Biosplice Therapeutics was founded in 2008.

Where is Biosplice Therapeutics headquartered?

Biosplice Therapeutics is headquartered in San Diego, California, United States.

What industry is Biosplice Therapeutics in?

Biosplice Therapeutics operates in Biotech, Healthcare.

How many employees does Biosplice Therapeutics have?

Biosplice Therapeutics has 51-200 employees.

Biosplice Therapeutics

Restoring health through first-in-class therapies harnessing alternative splicing

San Diego, United States · Founded 2008 · $120.0M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 51–200
Founded: 2008
Business Model: B2B

Website: biosplice.com
Total Funding: $120.0M
Last Round: $120.0M Series BApr 2021
Rounds: 1

About

Biosplice Therapeutics is a clinical-stage biopharmaceutical company pioneering therapeutic modulation of alternative pre-mRNA splicing. Founded in 2008 and based in San Diego, California, Biosplice's platform targets the CLK/DYRK family kinases that govern tissue-specific RNA splice-site selection. Its lead program, lorecivivint (LOR), a CLK2/DYRK1A inhibitor, has submitted a New Drug Application to the FDA for knee osteoarthritis treatment — potentially the first approved osteoarthritis drug in two decades. The company also has programs in Alzheimer's disease and oncology.

Summary

Biosplice Therapeutics is a Biotech company based in San Diego, United States, founded in 2008. It has raised $120.0M in total across 1 round, most recently a $120.0M Series B round in Apr 2021. Investors include SymBiosis II, Sands Capital and Eventide Asset Management.

LinkedIn X (Twitter)